News & Updates

Adding the PD-1/CTLA-4 bispecific antibody cadonilimab to chemotherapy improves overall survival (OS) and progression-free survival (PFS) in individuals with untreated, HER2-negative, locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) cancer, including patients with PD-L1–low tumours, according to the interim results of the phase III COMPASSION-15 trial.

Patients with atrial fibrillation receiving a reduced dose of direct acting oral anticoagulants (DOAC), particularly rivaroxaban and dabigatran, show a similar incidence of ischaemic stroke and systemic embolism to those receiving warfarin, a study has shown.